MY117535A - Hiv protease inhibitors - Google Patents

Hiv protease inhibitors

Info

Publication number
MY117535A
MY117535A MYPI98001071A MYPI9801071A MY117535A MY 117535 A MY117535 A MY 117535A MY PI98001071 A MYPI98001071 A MY PI98001071A MY PI9801071 A MYPI9801071 A MY PI9801071A MY 117535 A MY117535 A MY 117535A
Authority
MY
Malaysia
Prior art keywords
hiv protease
protease inhibitors
hiv
compounds
hiv virus
Prior art date
Application number
MYPI98001071A
Inventor
Albizati Kim
Reich Siegfried
Michael D Varney
Kanyin E Zhang
Kobayashi Takuo
Original Assignee
Agouron Pharma
Japan Tobacco Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Agouron Pharma, Japan Tobacco Inc filed Critical Agouron Pharma
Publication of MY117535A publication Critical patent/MY117535A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
    • C07D217/26—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/14—Nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/56—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/04—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D307/18—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D307/22—Nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D309/08—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D309/14—Nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D333/30—Hetero atoms other than halogen
    • C07D333/36—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D335/00—Heterocyclic compounds containing six-membered rings having one sulfur atom as the only ring hetero atom
    • C07D335/02—Heterocyclic compounds containing six-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

HIV PROTEASE INHIBITORS, OBTAINABLE BY CHEMICAL SYNTHESIS, INHIBIT OR BLOCK THE BIOLOGICAL ACTIVITY OF THE HIV PROTEASE ENZYME, CAUSING THE REPLICATION OF THE HIV VIRUS TO TERMINATE. THESE COMPOUNDS, AS WELL AS PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THESE COMPOUNDS AND OPTIONALLY OTHER ANTI-VIRAL AGENTS AS ACTIVE INGREDIENTS, ARE SUITABLE FOR TREATING PATIENTS OR HOSTS INFECTED WITH THE HIV VIRUS, WHICH IS KNOWN TO CAUSE AIDS.
MYPI98001071A 1997-03-13 1998-03-12 Hiv protease inhibitors MY117535A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US81595197A 1997-03-13 1997-03-13

Publications (1)

Publication Number Publication Date
MY117535A true MY117535A (en) 2004-07-31

Family

ID=25219265

Family Applications (1)

Application Number Title Priority Date Filing Date
MYPI98001071A MY117535A (en) 1997-03-13 1998-03-12 Hiv protease inhibitors

Country Status (35)

Country Link
EP (1) EP0970055A2 (en)
JP (1) JP2001516350A (en)
KR (1) KR100511089B1 (en)
CN (1) CN1179948C (en)
AP (1) AP1358A (en)
AR (1) AR012556A1 (en)
AU (1) AU743078B2 (en)
BG (1) BG63540B1 (en)
BR (1) BR9808867A (en)
CA (1) CA2284163A1 (en)
CO (1) CO4940496A1 (en)
CZ (1) CZ296647B6 (en)
EA (1) EA002378B1 (en)
EE (1) EE04114B1 (en)
GE (1) GEP20022764B (en)
HR (1) HRP980112A2 (en)
HU (1) HUP0001380A3 (en)
IL (2) IL131870A0 (en)
IS (1) IS5176A (en)
MX (1) MXPA99008395A (en)
MY (1) MY117535A (en)
NO (1) NO315555B1 (en)
NZ (1) NZ337706A (en)
OA (1) OA11196A (en)
PA (1) PA8448801A1 (en)
PE (1) PE58799A1 (en)
PL (1) PL192786B1 (en)
SA (1) SA98181116B1 (en)
SK (1) SK283636B6 (en)
SV (1) SV1998000038A (en)
TR (1) TR199902508T2 (en)
TW (1) TW200517112A (en)
UA (1) UA57772C2 (en)
WO (1) WO1998040357A2 (en)
ZA (1) ZA982047B (en)

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5484926A (en) * 1993-10-07 1996-01-16 Agouron Pharmaceuticals, Inc. HIV protease inhibitors

Also Published As

Publication number Publication date
MXPA99008395A (en) 2003-08-12
PA8448801A1 (en) 2000-05-24
OA11196A (en) 2003-05-21
IS5176A (en) 1999-09-10
IL131870A0 (en) 2001-03-19
HRP980112A2 (en) 1998-12-31
NO315555B1 (en) 2003-09-22
CA2284163A1 (en) 1998-09-17
AU743078B2 (en) 2002-01-17
EA002378B1 (en) 2002-04-25
CO4940496A1 (en) 2000-07-24
KR20000076236A (en) 2000-12-26
SV1998000038A (en) 1999-02-15
BG63540B1 (en) 2002-04-30
PE58799A1 (en) 1999-07-12
CZ319199A3 (en) 2000-06-14
HUP0001380A2 (en) 2000-09-28
AR012556A1 (en) 2000-11-08
CZ296647B6 (en) 2006-05-17
EP0970055A2 (en) 2000-01-12
SK122299A3 (en) 2000-05-16
KR100511089B1 (en) 2005-08-31
PL192786B1 (en) 2006-12-29
CN1179948C (en) 2004-12-15
WO1998040357A3 (en) 1998-11-26
BG103727A (en) 2000-04-28
BR9808867A (en) 2000-07-11
JP2001516350A (en) 2001-09-25
AU6457598A (en) 1998-09-29
TW200517112A (en) 2005-06-01
ZA982047B (en) 1998-09-28
AP1358A (en) 2004-12-03
UA57772C2 (en) 2003-07-15
AP9901648A0 (en) 1999-09-30
EE04114B1 (en) 2003-08-15
HUP0001380A3 (en) 2001-12-28
CN1253548A (en) 2000-05-17
NO994415L (en) 1999-11-10
IL131870A (en) 2006-04-10
PL335672A1 (en) 2000-05-08
TR199902508T2 (en) 2000-02-21
EA199900823A1 (en) 2000-04-24
WO1998040357A2 (en) 1998-09-17
NO994415D0 (en) 1999-09-10
GEP20022764B (en) 2002-08-26
SA98181116B1 (en) 2006-10-04
EE9900416A (en) 2000-04-17
SK283636B6 (en) 2003-11-04
NZ337706A (en) 2001-04-27

Similar Documents

Publication Publication Date Title
EP1340744A3 (en) Hiv protease inhibitors
DE69518840D1 (en) N-(3-amino-2-hydroxybutyl)sulfonamid-derivate as hiv-protease-inhibitoren
AP2003002915A0 (en) HIV protease inhibitors, compositions containing the same, their pharmaceutical uses and materials for their synthesis.
EA199800943A1 (en) UREA DERIVATIVES AND THEIR USE AS INHIBITORS INOSINE-5`-MONO-PHOSPHATE-DEHYDROGENASE INHIBITORS
BR0009485A (en) Method and compositions for preventing or reducing HIV infection by using leucine aminopeptidase inhibitors
ID21526A (en) 4-HYDROXYQUINOLIN-3-CARBOXOXIDE AND HYDRAZIDE AS ANTI-VIRUS INGREDIENTS
ATE377011T1 (en) GAMMA-HYDROXY-2-(FLUORALKYLAMINOCARBONYL)-1-PIPERAZINE PENTANAMIDE AS AN HIV PROTEASE INHIBITOR
GEP20104960B (en) USE OF [D-MeALa]3-[EtVal]4-CYCLOSPORIN FOR THE TREATMENT OF HEPATITIS C INFECTION AND PHARMACEUTICAL COMPOSITION COMPRISING SAID [D-MeAla]3-[EtVal]4-CYCLOSPORIN
AU4408597A (en) Anti-viral pharmaceutical compositions containing saturated 1,2-dithiaheterocyclic compounds and uses thereof
ES2132383T3 (en) PROTEASE HIV INHIBITORS.
MY132553A (en) Methods of making hiv-protease inhibitors and intermediates for making hiv-protease inhibitors
DE69828522D1 (en) ANTITROMOMBOTIC AGENTS
TW200517112A (en) Compounds and pharmaceutical composition for inhibiting HIV protease
NO20024522L (en) Compositions with anti-HIV activity
NO20001846L (en) New pharmaceutically active compounds, their preparation and use as ECE inhibitors
TH17013A (en) HIV protease inhibitors
TH14264B (en) HIV protease inhibitors
UA31078A (en) HUMAN IMMUNODEFICIENCY VIRUS INHIBITOR (DARIMID)
AP2003002938A0 (en) Intermediates for making HIV- protease inhibitors and methods of making HIV protease inhibitors.